Drug profile · INN
darbepoetin alfa
ARANESP
darbepoetin alfa (ARANESP) is a erythropoietin receptor agonist. Associated with Amgen. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — darbepoetin alfa
- US status
- approved
- Class
- Blood and blood forming organs (B03)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
darbepoetin alfa (ARANESP) is a erythropoietin receptor agonist. Associated with Amgen. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is darbepoetin alfa?
darbepoetin alfa (ARANESP) is a erythropoietin receptor agonist. Associated with Amgen. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for darbepoetin alfa?
ARANESP is a marketed brand name for darbepoetin alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of darbepoetin alfa?
darbepoetin alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.